| |
| |
| Exchange: |
New York Stock Exchange |
| Security
Type: |
Common |
| Shares
Out: |
956,580,000 |
| Market
Cap: |
796.44(B) |
| Last
Volume: |
1,747,701 |
Avg
Vol: |
3,278,293 |
| 52
Week Range: |
$434.7 - $815.06 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Drug Manufacturers - Major |
|
Member Indexes:
|
| |
S&P COMPOSITE 1500 |
|
NYSE COMPOSITE |
| |
S&P 500 |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 720 |
| Guru Rank Value : 1.4 |
| Guru Occurances : 2 |
|
|
|
|
|
| |
|
Company Profile Eli Lilly and Company discovers, develops, manufactures, and markets products in a single business segment: human pharmaceutical products. Co.'s products include: diabetes products, oncology products, immunology products, neuroscience products, and other therapies. Co.'s diabetes products include: Baqsimi®, Basaglar®, Humalog®, Humulin®, Jardiance®, Lyumjev®, Trajenta®, and Trulicity®. Co.'s oncology products include: Alimta®, Cyramza®, Erbitux®, Retevmo®, Tyvyt®, and Verzenio®. Co.'s immunology products include: Olumiant® and Taltz®. Co.'s neuroscience products include: Cymbalta®, Emgality®, Reyvow®, and Zyprexa®. Co.'s other therapies include: Bamlanivimab, Cialis®, and Forteo®.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
656 |
| Total Buy Value |
$0 |
$0 |
$0 |
$199,549 |
| Total People Bought |
0 |
0 |
0 |
1 |
| Total Buy Transactions |
0 |
0 |
0 |
1 |
| Total Shares Sold |
505,762 |
1,375,762 |
3,014,918 |
5,975,430 |
| Total Sell Value |
$409,104,400 |
$1,016,789,780 |
$2,147,483,647 |
$2,147,483,647 |
| Total People Sold |
3 |
3 |
4 |
6 |
| Total Sell Transactions |
10 |
22 |
49 |
89 |
| End Date |
2024-03-07 |
2023-12-05 |
2023-06-06 |
2022-06-06 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Shah Aarti S. |
SVP & CIO |
• – – |
2019-04-05 |
4 |
AS |
$125.85 |
$226,530 |
D/D |
(1,800) |
18,425 |
|
- |
|
| Lilly Endowment Inc |
10% Owner |
– – • |
2019-03-26 |
4 |
S |
$131.40 |
$26,938,688 |
D/D |
(205,000) |
116,810,304 |
|
- |
|
| Zakrowski Donald A |
Chief Accounting Officer |
• – – |
2019-03-22 |
4 |
AS |
$128.50 |
$128,500 |
D/D |
(1,000) |
4,595 |
|
- |
|
| Marram Ellen R |
Director |
– • – |
2019-03-18 |
4 |
A |
$125.24 |
$6,763 |
D/D |
54 |
56,590 |
|
- |
|
| Walker Karen |
Director |
– • – |
2019-03-18 |
4 |
A |
$125.24 |
$9,894 |
D/D |
79 |
372 |
|
- |
|
| Tai Jackson P |
Director |
– • – |
2019-03-18 |
4 |
A |
$125.24 |
$2,004 |
D/D |
16 |
54,333 |
|
- |
|
| Luciano Juan R |
Director |
– • – |
2019-03-18 |
4 |
A |
$125.24 |
$10,645 |
D/D |
85 |
8,421 |
|
- |
|
| Alvarez Ralph |
Director |
– • – |
2019-03-18 |
4 |
A |
$125.24 |
$10,896 |
D/D |
87 |
43,770 |
|
- |
|
| Barnes Melissa S |
Chief Eth/Cmpl Ofcr & SVP, ERM |
• – – |
2019-03-15 |
4 |
GD |
$0.00 |
$0 |
D/D |
1,815 |
20,270 |
|
- |
|
| Fry Stephen F |
SVP, HR & Diversity |
• – – |
2019-03-12 |
4 |
AS |
$123.16 |
$1,828,557 |
D/D |
(14,847) |
109,663 |
|
- |
|
| Shah Aarti S. |
SVP & CIO |
• – – |
2019-03-06 |
4 |
GD |
$0.00 |
$0 |
D/D |
1,105 |
17,320 |
|
- |
|
| Zakrowski Donald A |
Chief Accounting Officer |
• – – |
2019-03-01 |
4 |
AS |
$127.01 |
$127,010 |
D/D |
(1,000) |
5,595 |
|
- |
|
| Lilly Endowment Inc |
10% Owner |
– – • |
2019-03-01 |
4 |
S |
$127.45 |
$26,971,215 |
D/D |
(210,000) |
117,015,304 |
|
- |
|
| Lilly Endowment Inc |
10% Owner |
– – • |
2019-02-28 |
4 |
S |
$126.58 |
$25,345,017 |
D/D |
(200,000) |
117,225,304 |
|
- |
|
| Lilly Endowment Inc |
10% Owner |
– – • |
2019-02-22 |
4 |
S |
$124.19 |
$24,217,635 |
D/D |
(195,000) |
117,425,304 |
|
- |
|
| Luciano Juan R |
Director |
– • – |
2019-02-19 |
4 |
A |
$122.13 |
$10,625 |
D/D |
87 |
8,294 |
|
- |
|
| Marram Ellen R |
Director |
– • – |
2019-02-19 |
4 |
A |
$122.13 |
$6,717 |
D/D |
55 |
56,255 |
|
- |
|
| Tai Jackson P |
Director |
– • – |
2019-02-19 |
4 |
A |
$122.13 |
$1,954 |
D/D |
16 |
54,263 |
|
- |
|
| Lilly Endowment Inc |
10% Owner |
– – • |
2019-02-19 |
4 |
S |
$122.40 |
$25,108,513 |
D/D |
(205,000) |
117,620,304 |
|
- |
|
| Walker Karen |
Director |
– • – |
2019-02-19 |
4 |
A |
$122.13 |
$9,893 |
D/D |
81 |
292 |
|
- |
|
| Alvarez Ralph |
Director |
– • – |
2019-02-19 |
4 |
A |
$122.13 |
$10,870 |
D/D |
89 |
43,462 |
|
- |
|
| Norton Johna |
Senior VP, Global Quality |
• – – |
2019-02-16 |
4 |
D |
$122.48 |
$2,082 |
I/I |
(17) |
65 |
|
- |
|
| Norton Johna |
Senior VP, Global Quality |
• – – |
2019-02-16 |
4 |
OE |
$0.00 |
$0 |
I/I |
48 |
82 |
|
- |
|
| Conterno Enrique A |
SVP&Pres, LillyDiab & LillyUSA |
• – – |
2019-02-15 |
4 |
AS |
$121.00 |
$3,025,000 |
D/D |
(25,000) |
132,962 |
|
- |
|
| Harrington Michael J |
Senior VP and General Counsel |
• – – |
2019-02-11 |
4 |
GA |
$0.00 |
$0 |
I/I |
62,500 |
62,500 |
|
- |
|
1437 Records found
|
|
Page 29 of 58 |
|
|
1.33 (0.16%) 
